Literature DB >> 17768129

Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells.

Cindy Grandjenette, Anne Kennel, Gilbert C Faure, Marie C Béné, Pierre Feugier.   

Abstract

This study reports that B-chronic lymphocytic leukemia (B-CLL) cells display the same pattern of toll-like receptors (TLRs) proteins expression as normal B-cells, yet with overexpression of TLR9. Furthermore, TLR7 and TLR9 appear to be functional and liable to respond to specific ligands, respectively imidazoquinolines and CpG-ODN thus potentially opening new therapeutic approaches.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17768129     DOI： 10.3324/haematol.10975

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  14 in total

1.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Authors:  Eleni Arvaniti; Stavroula Ntoufa; Nikos Papakonstantinou; Tasoula Touloumenidou; Nikolaos Laoutaris; Achilles Anagnostopoulos; Klea Lamnissou; Federico Caligaris-Cappio; Kostas Stamatopoulos; Paolo Ghia; Marta Muzio; Chrysoula Belessi
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

2.  Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Authors:  Kristine L Holm; Randi L Indrevaer; June Helen Myklebust; Arne Kolstad; Jan Øivind Moskaug; Elin H Naderi; Heidi K Blomhoff
Journal:  Immunology       Date:  2016-07-25       Impact factor: 7.397

3.  Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

Authors:  Stavroula Ntoufa; Anna Vardi; Nikos Papakonstantinou; Achilles Anagnostopoulos; Vassiliki Aleporou-Marinou; Chrysoula Belessi; Paolo Ghia; Federico Caligaris-Cappio; Marta Muzio; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

4.  Mantle cell lymphoma activation enhances bortezomib sensitivity.

Authors:  Sarah K Brennan; Brooke Meade; Qiuju Wang; Akil A Merchant; Jeanne Kowalski; William Matsui
Journal:  Blood       Date:  2010-06-22       Impact factor: 22.113

5.  Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.

Authors:  Ying Tan; Amanda A Watkins; Benjamin B Freeman; John A Meyers; Ian R Rifkin; Adam Lerner
Journal:  J Immunol       Date:  2015-01-01       Impact factor: 5.422

6.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

7.  Toll-like Receptors in Chronic Lymphocytic Leukemia.

Authors:  Marta Muzio; Eleonora Fonte; Federico Caligaris-Cappio
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-08-09       Impact factor: 2.576

8.  The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia.

Authors:  Justyna Rybka; Aleksandra Butrym; Tomasz Wróbel; Bożena Jaźwiec; Aleksandra Bogucka-Fedorczuk; Rafał Poręba; Kazimierz Kuliczkowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-01-12       Impact factor: 4.291

Review 9.  Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

Authors:  Walaa Darwiche; Brigitte Gubler; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

10.  GIFT4 fusokine converts leukemic B cells into immune helper cells.

Authors:  Jiusheng Deng; Andrea Pennati; Jonathon B Cohen; Yuanqiang Wu; Spencer Ng; Jian Hui Wu; Christopher R Flowers; Jacques Galipeau
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.